Market Overview

UPDATE: Amgen Will Receive Exclusive Global Rights To Develop, Commercialize Up To 3 Added, Undisclosed Targets; CytomX Eligible To Receive Up To $950M In Added Upfront, Milestone Payments Should Amgen Pursue All Targets

Partner Center

Loading...